fig4

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer

Figure 4. Structures of new HDAC inhibitors with promising activities against CRPC. HDAC: Histone deacetylase; CRPC: castration-resistant prostate cancer; AR: androgen receptor; EGFR: epidermal growth factor receptor; PI3K: phosphatidylinositol 3-kinase.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/